Breast Cancer

Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.
OlympiAD provides proof of principle that breast cancers with defects in a specific DNA damage repair pathway are sensitive to a targeted therapy designed to exploit that defect, said Dr Robson.
CDK4/CDK6 inhibitors will most likely not have a role as monotherapy, said Ingrid Mayer, MD, Associate Professor of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, who discussed the study results.

During each patient’s laboratory work-up, oncology specialists rely on findings related to the tumor’s estrogen receptor (ER) and progesterone receptor status, as well as the amplification and overexpression of the human epidermal growth factor receptor 2 (HER2), to direct treatment planning.2,3

CDK4/CDK6 inhibitors are a promising addition to the armamentarium for the treatment of patients with breast cancer. At the 42nd annual meeting of the Oncology Nursing Society, 2 experts discussed the role of these new drugs, and how to factor them into treatment decisions.
The largest study to date comparing outcomes of radiation therapy and postmastectomy breast reconstruction found higher rates of complication and failure in women who received radiation therapy and had implant reconstruction versus autologous reconstruction.
Endocrine therapy is known to reduce breast cancer risk by 30% when used as primary prevention in women at risk for the disease, and the reduction lasts for at least 20 years.
Breast cancer rates are increasing worldwide, paralleling increases in type 2 diabetes, obesity, and metabolic syndrome (MetS).
Breast density, which can affect the visualization of mammography, is one of the strongest and most consistent risk factors for breast cancer.
Occupational factors such as shift work disrupt circadian rhythm and can increase breast cancer risk, and the International Agency for Research on Cancer has classified shift work as a possible carcinogen.
Page 4 of 15
Results 31 - 40 of 146